Fluorenyl-(4)-essigsaeure | 41146-80-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: Fluorenyl-(4)-essigsaeure
• 英文别名: Fluoren-1-yl-essigsaeure；Fluoren-1-essigsaeure；Fluorenessigsaure；2-(9H-fluoren-1-yl)acetic acid
• CAS: 41146-80-9
• 化学式: C₁₅H₁₂O₂
• 分子量: 224.259
• InChiKey: FWXBGNBHFVBIAE-UHFFFAOYSA-N

物化性质

• 沸点：
  422.2±14.0 °C(Predicted)
• 密度：
  1.275±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  Fluorenyl-(4)-essigsaeure 在 溴 作用下， 生成 9-Brom-fluoren-1-yl-essigsaeure
  参考文献：
  名称：

  The Effect of Carboxyl Groups in Neighboring Side Chains on the Hydrolysis of Substituted Benzyl and Fluorenyl Bromides

  摘要：

  DOI：

  10.1021/jo01349a063
• 作为产物：
  描述：

  重氮甲烷 、 芴-1-羧酸 生成 Fluorenyl-(4)-essigsaeure
  参考文献：
  名称：

  The Effect of Carboxyl Groups in Neighboring Side Chains on the Hydrolysis of Substituted Benzyl and Fluorenyl Bromides

  摘要：

  DOI：

  10.1021/jo01349a063

文献信息

• Pd(II)-catalyzed Enantioselective Beta-Methylene C(sp3)–H Bond Activation
  申请人：The Scripps Research Institute

  公开号：US20190315710A1

  公开（公告）日：2019-10-17

  Chiral acetyl-protected aminoethyl quinoline (APAQ), pyridine and imazoline ligands are disclosed that enable Pd (II)-catalyzed enantioselective arylation or heteroarylation of ubiquitous prochiral β-methylene C—H bonds of aliphatic amides offers an alternative disconnection for constructing β-chiral centers. Systematic tuning of the ligand structure reveals that a six-membered instead of a five-membered chelation of these types of ligands with the Pd(II) is important for accelerating the C(sp 3 )-H activation thereby achieving enantioselectivity for quinoline and pyridine ligands.

  披露了手性乙酰保护氨基乙基喹啉（APAQ）、吡啶和咪唑啉配体，这些配体使Pd（II）催化的对丙烷酰胺的普遍的原始手性β-亚甲基C-H键进行对芳基或杂芳基化的不对称选择性取代反应成为可能，为构建β-手性中心提供了另一种断裂途径。通过系统调整配体结构发现，这些类型的配体与Pd（II）的六元环而不是五元环的螯合对于加速C（sp3）-H键的活化至关重要，从而实现喹啉和吡啶配体的对映选择性。
• [EN] SYNTHESIS OF 6-METHYL-N1-(4-(PYRIDIN-3-YL)PYRIMIDIN-2-YL)BENZENE-1,3-DIAMINE<br/>[FR] SYNTHÈSE DE 6-MÉTHYL-N1-(4-(PYRIDIN-3-YL)PYRIMIDIN-2-YL)BENZÈNE-1,3-DIAMINE
  申请人：ESCO ASTER PTE LTD

  公开号：WO2021074138A1

  公开（公告）日：2021-04-22

  Processes and useful intermediates for the synthesis of the tyrosine kinase inhibitors Formula (II) nilotinib and Formula (IV) imatinib. Key intermediates, method for their synthesis and their use in a divergent synthesis, making use of a Curtius rearrangement, to nilotinib and imatinib are described.

  用于合成酪氨酸激酶抑制剂 Formula (II) 尼洛替尼和 Formula (IV) 伊马替尼的过程和有用中间体。描述了关键中间体、其合成方法以及它们在分散合成中的使用，利用库尔修斯重排法制备尼洛替尼和伊马替尼。
• NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF
  申请人：TAIHO PHARMACEUTICAL CO., LTD.

  公开号：US20180009818A1

  公开（公告）日：2018-01-11

  The problem to be solved by the present invention is to provide a novel compound having RET inhibitory activity. The present invention also provides a pharmaceutical preparation that is useful for the prevention and/or treatment of RET-related diseases, particularly cancer, based on RET inhibitory activity. The present invention provides a compound represented by Formula (I): wherein A, R 2 , and X are as defined in the specification; or a salt thereof.

  本发明要解决的问题是提供一种具有RET抑制活性的新型化合物。本发明还提供了一种药物制剂，基于RET抑制活性，用于预防和/或治疗与RET相关的疾病，特别是癌症。本发明提供了一种由以下式表示的化合物：其中A、R2和X如规范中定义；或其盐。
• [DE] PYRIDAZINDERIVATE<br/>[EN] PYRIDAZINE DERIVATIVES<br/>[FR] DERIVES DE PYRIDAZINE
  申请人：MERCK PATENT GMBH

  公开号：WO2003104204A1

  公开（公告）日：2003-12-18

  Pyridazinderivate der Formel (I), wirken als Phosphodiesterase IV-Inhibitoren und lassen sich zur Behandlung von Osteoporose, Tumoren, Kachexie, Atherosklerose, rheumatoider Arthritis, multipler Sklerose, Diabetes mellitus, entzündlichen Prozessen, Allergien, Asthma, Autoimmunkrankheiten, Myokarderkrankungen und AIDS einsetzen.

  化合物（I）的吡啶二唑衍生物作为磷酸二酯酶IV抑制剂，可用于治疗骨质疏松症、肿瘤、消瘦症、动脉粥样硬化、类风湿性关节炎、多发性硬化症、糖尿病、炎症过程、过敏、哮喘、自身免疫疾病、心肌病和艾滋病。
• SELF-ASSEMBLING PEPTIDES BEARING ORGANIC ELECTRONIC FUNCTIONALITY AND APPLICATIONS EMPLOYING THE SAME
  申请人：Tovar John Dayton

  公开号：US20120101022A1

  公开（公告）日：2012-04-26

  The aqueous self-assembly of oligopeptide-flanked π-conjugated molecules into discrete one-dimensional nanostructures is described. Unique to these molecules is the fact that the π-conjugated unit has been directly embedded within the peptide backbone by way of a synthetic amino acid with π-functionality that is compatible with standard Fmoc-based peptide synthesis or by way of a diacid or other bis(electrophile) that can covalently cross-link peptide chains presented on a synthesis support. The peptide-based molecular designs enforce intimate π-π communication within the aggregates after charge-screening and self-assembly, making these nanostructures attractive for optical or electronic applications in biological environments. In other embodiments, a convenient method to incorporate π-electron units into peptides that assemble into amyloid-like supramolecular polymers is disclosed. Self-assembly manipulates these “electronic peptides” into delocalized sub-10 nm one dimensional (1-D) nanostructures under completely aqueous conditions.

  本文介绍了寡肽-π共轭分子在水相中自组装成离散一维纳米结构的过程。这些分子的独特之处在于，π共轭单元直接嵌入到寡肽骨架中，通过合成具有π功能的氨基酸，该氨基酸与标准的Fmoc基肽合成兼容，或通过二酸或其他双(亲电子)与合成支撑上呈现的肽链共价交联。寡肽分子的设计在电荷屏蔽和自组装后强制实现聚集体内部的亲-亲作用，使这些纳米结构在生物环境中具有光学或电子应用的吸引力。在其他实施例中，本文还揭示了一种将π电子单元方便地纳入到聚集成类淀粉样超分子聚合物的寡肽中的方法。自组装将这些“电子寡肽”操纵成分散的亚10纳米一维(1-D)纳米结构，在完全水相条件下实现。